Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results

Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat

Jefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following the company's 3Q results. VRX reported revenues of $2.79B vs the Street's $2.78B. EPS was reported at $2.74 vs the Street's $2.72.

Analyst David Steinberg... More

CIBC Downgrades Valeant Pharmaceuticals (VRX) to Sector Perform

CIBC downgraded Valeant Pharmaceuticals (NYSE: VRX) from Sector Outperform to Sector Perform.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $163.83 yesterday.

Mizuho Securities Remains Neutral After Valeant Pharma (VRX) Reports 2c EPS Beat

Mizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings report. Revenues of $2.80B beat consensus estimates of $2.79B and EPS of $2.74 came in $0.02 higher. Management raised full year revenue guidance to $11.0-$11.2B and... More

BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance

BMO Capital maintained an Outperform rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $265.00 (from $273.00), following the company's 3Q15 earnings results. VRX beat expectations for the quarter, however, the results showed that the legacy business had underperformed.

Analyst Alex Arfaei... More

Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS Outlook

Valeant Pharma (NYSE: VRX) reported Q3 EPS of $0.14, versus $0.81 reported last year. Revenue for the quarter came in at $2.79 billion, versus $2.06 billion reported last year.

"Today, we reported yet another consecutive quarter of strong financial results that exceeded expectations," stated J. Michael... More